LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Kodu・Aktsiate loetelu・BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc

Suletud

SektorTervishoid

53.4 -0.74

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

53.1

Max

53.42

Põhinäitajad
By Trading Economics
Sissetulek	-457M -31M
Müük	-49M 776M
P/E Sektori keskmine	20.457 80.03
Aktsiakasum	1.44
Kasumimarginaal	-3.961
Töötajad	3,040
EBITDA	-324M -5.3M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+60.82% upside

Turustatistika
By TradingEconomics
Turukapital	111M 11B
Eelmine avamishind	54.14
Eelmine sulgemishind	53.4

Uudiste sentiment

By Acuity

67%

33%

333 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

59.405 / 62.19 Toetus ja vastupanu

BioMarin Pharmaceutical Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. dets 2025, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Brookfield, GIC Agree $4.5 Billion Deal for Australia's National Storage -- Update

5. dets 2025, 21:08 UTC

Omandamised, ülevõtmised, äriostud

Meta Platforms Buys AI-Device Maker Limitless

5. dets 2025, 19:39 UTC

Suurimad hinnamuutused turgudel

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5. dets 2025, 19:17 UTC

Omandamised, ülevõtmised, äriostud

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

7. dets 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

7. dets 2025, 23:05 UTC

Market Talk

RBA Set to Remain 'Emphatically' On Hold, Westpac Says -- Market Talk

7. dets 2025, 22:18 UTC

Market Talk

RBA Set To Conclude Year With Hawkish Message -- Market Talk

6. dets 2025, 16:52 UTC

Omandamised, ülevõtmised, äriostud

As Netflix Swoops In to Buy Warner Bros., We Revisit the Studio's Long, Twisted Journey -- Barrons.com

6. dets 2025, 10:30 UTC

Omandamised, ülevõtmised, äriostud

Why Netflix Shareholders Aren't Thrilled to Acquire Warner Bros. -- Heard on the Street -- WSJ

6. dets 2025, 02:38 UTC

Omandamised, ülevõtmised, äriostud

How a Netflix-Warner Deal Would Change Everything in Hollywood -- Again -- WSJ

5. dets 2025, 21:59 UTC

Omandamised, ülevõtmised, äriostud

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5. dets 2025, 21:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

5. dets 2025, 21:50 UTC

Omandamised, ülevõtmised, äriostud

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5. dets 2025, 21:36 UTC

Market Talk

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5. dets 2025, 21:35 UTC

Omandamised, ülevõtmised, äriostud

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5. dets 2025, 21:26 UTC

Omandamised, ülevõtmised, äriostud

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5. dets 2025, 21:12 UTC

Market Talk

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5. dets 2025, 21:03 UTC

Market Talk

Tulu

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5. dets 2025, 21:01 UTC

Market Talk

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5. dets 2025, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5. dets 2025, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5. dets 2025, 20:42 UTC

Omandamised, ülevõtmised, äriostud

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5. dets 2025, 20:01 UTC

Omandamised, ülevõtmised, äriostud

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5. dets 2025, 19:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. dets 2025, 19:44 UTC

Market Talk

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5. dets 2025, 19:39 UTC

Market Talk

Silver Climbs to a New Record High -- Market Talk

5. dets 2025, 19:31 UTC

Omandamised, ülevõtmised, äriostud

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5. dets 2025, 18:30 UTC

Market Talk

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5. dets 2025, 18:28 UTC

Omandamised, ülevõtmised, äriostud

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5. dets 2025, 18:24 UTC

Omandamised, ülevõtmised, äriostud

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

BioMarin Pharmaceutical Inc Prognoos

Hinnasiht

By TipRanks

60.82% tõus

12 kuu keskmine prognoos

Keskmine 85.88 USD 60.82%

Kõrge 120 USD

Madal 55 USD

Põhineb 19 Wall Streeti analüütiku instrumendi BioMarin Pharmaceutical Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

19 ratings

Osta

Hoia

Müü

Põhineb 19 analüütiku instrumendi BioMarin Pharmaceutical Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

59.405 / 62.19Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

333 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.